WEBULL
WebtradeDownload

Bayer (XTRA:BAYN) After Its Q2 Earnings Beat Still Looks Undervalued To Bulls

Simply Wall St · 1d ago

Bayer (XTRA:BAYN) is back in focus after its Q2 2026 earnings beat, a swing to profit, stronger Crop Science performance supported by U.S. dicamba approvals, and a reduced year end net debt outlook.

See our latest analysis for Bayer.

At a share price of €49.81, Bayer has picked up momentum, with a 90 day share price return of 34.69% and a 1 year total shareholder return of 94.26%, even though the 3 year total shareholder return declined 4.14%. This suggests recent enthusiasm has followed the profit swing, Crop Science progress and balance sheet updates.

If Bayer’s move has your attention, this could be a good moment to see what else is gaining traction in related themes through our nuclear energy infrastructure stock screener 89 nuclear energy infrastructure stocks

After Bayer’s sharp rebound and return to profit, the tension now is between riding the momentum and waiting for a cleaner entry. How does the current valuation compare with the recent reset in expectations?

Most Popular Narrative: 9.3% Undervalued

The most followed narrative currently places Bayer’s fair value at €54.92, above the last close at €49.81. That gap is built on detailed earnings and margin assumptions.

Ongoing margin expansion and operational efficiency initiatives, such as the streamlining of Crop Science production, cost saving efforts targeting €1b in annual improvements, and targeted restructuring in Consumer Health, are expected to enhance long term net margins and cash flow conversion, particularly as regulatory disruptions in key crop protection products abate from 2026 onward.

Read the complete narrative. Read the complete narrative.

Want to understand why this narrative sees room above today’s price for Bayer? The answer sits in a specific mix of revenue growth, margin rebuild and the earnings multiple that ties it all together.

Result: Fair Value of €54.92 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, Bayer’s glyphosate and PCB litigation exposure, along with regulatory pressure on crop protection products like dicamba and Movento, could quickly challenge this valuation narrative.

Find out about the key risks to this Bayer narrative.

Next Steps

If this Bayer story sounds optimistic, it is worth checking the underlying data yourself and deciding how convincing it feels to you. To see what those positive factors look like in detail, take a closer look at the 3 key rewards.

Looking for more Bayer investment ideas?

If Bayer has sharpened your focus, do not stop here. Use the Simply Wall Street Screener to spot other opportunities that fit your style before the market moves.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.